Evolutec to Drop Allergy Product ; Business News IN BRIEF
January 4, 2007
Shares in the biopharma-ceutical firm Evolutec fell 14 per cent after it said it will stop investing in rEV131, a treatment for allergic, inflammatory and auto-immune disease, after it found no significant differences between the product and a placebo. Its shares fell 2.5p to 15.5p.
(c) 2007 Independent, The; London (UK). Provided by ProQuest Information and Learning. All rights Reserved.